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Abstract
Background: The acute phase of abstinence from methamphetamine abuse is critical for rehabilitation success. Proton 
magnetic resonance spectroscopy has detected below-normal levels of glutamate+glutamine in anterior middle cingulate 
of chronic methamphetamine abusers during early abstinence, attributed to abstinence-induced downregulation of the 
glutamatergic systems in the brain. This study further explored this phenomenon.
Methods: We measured glutamate+glutamine in additional cortical regions (midline posterior cingulate, midline precuneus, 
and bilateral inferior frontal cortex) putatively affected by methamphetamine. We examined the relationship between 
glutamate+glutamine in each region with duration of methamphetamine abuse as well as the depressive symptoms of 
early abstinence. Magnetic resonance spectroscopic imaging was acquired at 1.5 T from a methamphetamine group of 44 
adults who had chronically abused methamphetamine and a control group of 23 age-, sex-, and tobacco smoking-matched 
healthy volunteers. Participants in the methamphetamine group were studied as inpatients during the first week of 
abstinence from the drug and were not receiving treatment.
Results: In the methamphetamine group, small but significant (5–15%, P < .05) decrements (vs control) in 
glutamate+glutamine were observed in posterior cingulate, precuneus, and right inferior frontal cortex; 
glutamate+glutamine in posterior cingulate was negatively correlated (P < .05) with years of methamphetamine abuse. The 
Beck Depression Inventory score was negatively correlated (P < .005) with glutamate+glutamine in right inferior frontal cortex.
Conclusions: Our findings support the idea that glutamatergic metabolism is downregulated in early abstinence in multiple 
cortical regions. The extent of downregulation may vary with length of abuse and may be associated with severity of 
depressive symptoms emergent in early recovery.
Keywords: methamphetamine, abstinence, glutamate, magnetic resonance spectroscopy, depression
Introduction
Methamphetamine abuse, a major illicit drug problem (Gonzales 
et al., 2010), is resistant to treatment. Psychosocial interventions, 
the core of contemporary treatment for stimulant-use disorders, 
relieve only a portion of sufferers (Rawson et al., 2004), but effec-
tive medications are unknown (Shoptaw et al., 2009). Most stimu-
lant abusers enter treatment in the first 7 to 10 days of abstinence 
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(Elkashef et al., 2007), the acute phase of withdrawal (Zorick et al., 
2010). In this acute phase, risk of noncompliance is high, crucially 
affecting engagement, retention, and treatment outcome (Brecht 
et al., 2000). For this reason, neuroimaging at our center (London 
et al., 2004; Thompson et al., 2004; Berman et al., 2008; Tobias et al., 
2010; Morales et al., 2012) and a few others (Kim et al., 2005 2009; 
Ernst and Chang 2008) has focused on characterizing the brain in 
acute abstinence from methamphetamine to inform development 
of novel and improved avenues to remediation.
 Proton magnetic resonance spectroscopy (MRS) is a noninva-
sive neuroimaging technique used in several studies, mainly of 
longer term abstinence from methamphetamine (Ernst et al., 2000; 
Nordahl et al., 2002 2005; Sekine et al., 2002; Chang et al., 2005; 
Salo et al., 2007 2011a 2011b; Sung et al., 2007; Taylor et al., 2007; 
Sailasuta et al., 2010; Cloak et al., 2011; Howells et al., 2014). MRS 
assays the concentrations of several key metabolites potentially 
affected by methamphetamine in the living human brain. Ernst 
and Chang (2008) partly characterized the metabolic state of the 
brain in early abstinence with MRS. They identified one putative 
feature of this state: below-normal levels of glutamate+glutamine 
(Glx). Glx is a signal forming part of the MR spectrum; the magni-
tude of this signal is proportional to the sum of the concentrations 
of the amino acid and excitatory neurotransmitter glutamate (Glu) 
and the closely related neutral amino acid glutamine (Gln). The 
structural affinity of Glu and Gln renders them challenging to dis-
tinguish with MRS; hence, they are often assayed as a combined 
entity, Glx. Ernst and Chang (2008) showed evidence for a depletion 
of these glutamatergic compounds in methamphetamine abuse. 
In the first 2 months of abstinence, they measured below-normal 
Glx in anterior middle cingulate. (The anterior middle cingulate 
is located just caudal and dorsal to the portion of the cingulate 
that caps the genu of the corpus callosum; O’Neill et al., 2009). The 
authors deduced that low Glx corresponded to a downregulation 
of brain Glu-Gln systems induced in early abstinence, perhaps a 
rebound from elevated levels of these compounds prevailing in 
times of active abuse. Their interpretation was supported by a pos-
itive correlation between Glx and length of abstinence (ie, recovery 
of Glx) across their sample as well as by within-subject increases 
in Glx observed longitudinally during the course of abstinence. 
Multiple neurochemical interpretations of these findings were 
offered, including methamphetamine-associated disturbances in 
the Krebs cycle and/or the neuronal-astrocytic Glu-Gln cycle as 
well as cell damage and microglial activation.
 Here, we further explore low Glx in early abstinence from meth-
amphetamine. We sought to determine if the putative Glx deficit 
manifests in cortical regions beyond anterior middle cingulate. 
Thereby, we targeted regions implicated in methamphetamine 
abuse in prior work using other neuroimaging modalities. One 
such region was the medial parietal cortex. Using 18FDG-PET, 
Volkow et  al. (2001) established that methamphetamine-abus-
ing subjects abstinent for 2 weeks to 2 years had above-normal 
absolute cerebral metabolic rate of glucose (CMRglc) in medial 
parietal cortex. We later showed that research participants who 
had chronically used methamphetamine and then maintained 
abstinence for 4 to 7  days showed elevated relative CMRglc in 
medial parietal cortex and adjacent posterior middle cingulate 
cortex (London et al., 2004) and that CMRglc increased during the 
first month of abstinence from methamphetamine, especially in 
medial parietal cortex (Berman et al., 2008). Given the metabolic 
coupling between Glu and CMRglc in brain (Sibson et al., 1998), 
such effects might also influence the MRS Glx peak. We divided 
the medial parietal target into posterior cingulate cortex and the 
immediately dorsal precuneus, a division motivated by our earlier 
structural MRI work that had revealed below-normal gray-matter 
volume in methamphetamine-abusing subjects in posterior cin-
gulate, but not precuneus (Thompson et al., 2004). A second target 
region was inferior frontal cortex, selected because the right infe-
rior frontal cortex has been assigned a special role in behavioral 
response inhibition (Aron et al., 2014), which is impaired in sub-
jects during early abstinence from chronic methamphetamine 
abuse (Monterosso et  al., 2005). In addition, we have observed 
a deficit in gray matter of right inferior frontal gyrus in these 
subjects (Thompson et al., 2004; Tabibnia et al., 2011). This defi-
cit partly recovers in the course of longer abstinence (Morales 
et al., 2012). We hypothesized that Glx would be below normal in 
dorsal posterior cingulate, precuneus, and inferior frontal cortex 
and that Glx in these regions would be negatively correlated with 
duration of methamphetamine abuse. If low cortical Glx is a fea-
ture of early abstinence from methamphetamine, then it might 
contribute to behavioral symptoms during early abstinence, such 
as depressive symptoms (Newton et al., 2004; Zorick et al., 2010). 
We hypothesized that Glx in our target regions would be nega-
tively correlated with the severity of depressive symptoms, meas-
ured by the Beck Depression Inventory (BDI; Beck et al., 1996). We 
tested these hypotheses in an inpatient sample of early (4–7 days) 
abstinent methamphetamine-abusing subjects and age-and sex-
matched healthy control subjects.
Methods
Subjects
Forty-four methamphetamine-abusing and 24 healthy con-
trol subjects (Table  1), recruited via local print and radio ads, 
Table 1. Clinical Characteristics of Study Subjects.
Methamphetamine (n = 44) Control (n = 24) P
Sex 0.833
 Female 19 11 --
 Male 25 13 --
Age, yr 33.0 ± 9.4 33.0 ± 7.4 0.989
Depression, BDI Score 13.3 ± 11.5 1.8 ± 2.5 <0.0005
Years Meth Abuse 11.1 ± 7.8 0 --
g/week Meth 1.9 ± 1.4 0 --
Pack-Years Tobacco 10.9 ± 11.6 9.3 ± 8.0 0.508
Fagerström Score 3.0 ± 2.2 3.5 ± 2.3 0.474
day/month Marijuana 0.7 ± 1.2 0.4 ± 1.3 0.439
drink/week Ethanol 1.6 ± 2.3 2.6 ± 2.5 0.113
Shown are subject numbers or group mean±standard deviation. P values are for χ2 (sex) or two-way independent t-tests (all other variables). 
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were enrolled into 2 groups: methamphetamine and control. 
Inclusion criteria for both groups were: (1) moderate or above 
intelligence (score >85 on the Shipley Institute of Living Scale; 
Zachary 1985), (2) right-handedness (score >20 on a modified 
Edinburgh Handedness Test), (3) taking no prescription medi-
cations or herbal products (eg, Ginkgo biloba) expected to affect 
brain function, and (4) no current Axis I psychiatric disorders, 
including substance dependence disorders other than nicotine 
dependence (or methamphetamine dependence for the meth-
amphetamine group). Absence of psychiatric disorders was 
established by in-person screening with the Structured Clinical 
Interview for DSM-IV. All participants with a history of notable 
head trauma, neurological disease, cardiovascular or pulmonary 
disease, or other significant major medical conditions, such as 
seropositivity for HIV, were excluded. Because of the high preva-
lence of tobacco smoking among methamphetamine-abusing 
subjects, an effort was made to match the 2 groups for cigarette 
smoking. Recent smoking was verified by carbon monoxide lev-
els in expired air ≥10 ppm (Micro smokerlyzer; Bedfont Scientific 
Ltd, Kent, UK) and the presence of urinary cotinine (≥200 ng/
mL by Accutest NicAlert strips; JANT Pharmacal Corporation, 
Encino, CA). Mean nicotine dependence (Fagerström score), 
cumulative lifetime exposure (pack-years) to tobacco, marijuana 
consumption (days in past 30  days), and ethanol consump-
tion did not differ significantly between groups (Table 1). After 
receiving a detailed explanation of the study, all subjects gave 
written informed consent to participate.
 Participants in the methamphetamine group resided in the 
UCLA General Clinical Research Center inpatient unit during 
their participation. They all denied a desire to seek treatment 
yet were willing to remain abstinent from methamphetamine 
for the course of the study and were paid for their participa-
tion, including remaining abstinent from methamphetamine. 
These participants had to satisfy DSM-IV criteria (established by 
Structured Clinical Interview) for methamphetamine depend-
ence and demonstrate use of methamphetamine within 3 days 
of enrollment, as verified by a positive urine toxicology screen. 
Thereafter, subjects were under regular supervision of medical 
staff and underwent twice-weekly random urine screens to con-
firm abstinence from illicit drugs of abuse. Methamphetamine 
abuse variables, including duration of abuse in years and cur-
rent intensity of methamphetamine abuse in grams per week 
(Table 1), were solicited by structured interview at the time of 
enrollment. Participants in the control group were matched to 
the methamphetamine group for age and sex (Table 1). MR scans 
were performed within 4 to 7 days of admission, and participants 
in both groups evidenced negative urine screens on the day of 
the scan. In the same timeframe, the BDI was administered to 
assess depressive symptoms. In early abstinence, methamphet-
amine-dependent subjects exhibit depressive symptoms and 
symptoms of psychosis, both of which largely resolve within a 
week of abstinence, although drug craving does not significantly 
decrease from the time of initiating abstinence until the second 
week (Zorick et al., 2010). The study was approved by the UCLA 
Office for Protection of Human Subjects.
Magnetic Resonance Acquisition
Proton MRS imaging (MRSI), the multivoxel version of MRS, and 
prescriptive structural MRI were acquired together in a single 
session. Acquisitions were performed on a 1.5-T magnetic reso-
nance scanner (Siemens Sonata) using a standard quadrature 
head coil. In addition to MRSI, scanning sequences included a 
localizer scout and a high-resolution T1-weighted whole-brain 
MRI. Water-suppressed PRESS MRSI (repetition time = 1500 ms, 
echo time = 30 ms, number of excitations = 8, in-plane resolu-
tion: 11 x 11 mm2, slab thickness: 12 mm for medial parietal 
or 9 mm for inferior frontal with nominal voxel size 1.4 or 1.1 
cc, respectively) was acquired from three 2-dimensional slabs 
(Figure  1). The first slab was oriented sagitally and straddled 
the longitudinal midline sampling posterior cingulate cortex 
ventrally and precuneus dorsally. The posterior cingulate was 
a mixture of dorsal and ventral posterior cingulate cortex, as 
defined by Vogt (O’Neill et al., 2009). The second and third slabs 
were sagittal-oblique (roughly parallel to the ipsilateral temple) 
in orientation and sampled the left, respectively right, peri-Syl-
vian region, including inferior frontal gyrus and other nearby 
cortex. Each of the 3 MRSI slabs was followed by an identical 
acquisition (only 1 number of excitation) with water-suppres-
sion turned off.
Figure 1. Sagittal (A), axial-oblique (B), and coronal-oblique (C) magnetic resonance imaging (MRI) of the brain showing “medial parietal” magnetic resonance spec-
troscopy imaging (MRSI) slab. The white square in a is A 12-mm–thick PRESS-select volume, consisting of 4 x 4 MRSI voxels, each 11 x 11 mm2 in-plane; the blue square 
within the white square is one such voxel. The rear edge of the slab was aligned parallel to the parieto-occipital sulcus; the lower edge was parallel or tangent to the 
dorsal margin of the isthmus or splenium of the corpus callosum. The most ventral voxel row samples posterior cingulate (blue square) and dorsal rows sample mainly 
precuneus. Sagittal-oblique (D), coronal (E), and axial-oblique (F) MRI depicting positioning of 9-mm–thick MRSI slabs in peri-Sylvian region. The PRESS volume was 
aligned parallel to the temple, set approximately 2 cm deep into the brain, sized to anatomy, and rotated counter-clockwise parallel to the Sylvian fissure to sample 
inferior frontal cortex (blue square in D-F).
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Magnetic Resonance Postprocessing
The whole-brain T1-weighted volume of each subject was trans-
formed into ICBM152 stereotaxic space, skull-stripped, and seg-
regated into gray-matter, white-matter, and cerebrospinal fluid 
(CSF) subvolumes using the Statistical Parametric Mapping 5 soft-
ware suite. Each whole-brain tissue subvolume was converted 
into a binary mask and transformed back into native space.
 MRSI spectra were automatically fit with LCModel, yield-
ing fitted peaks with absolute metabolite levels referenced to 
the unsuppressed water resonance and expressed in IU. Fitted 
peaks included Glx as well as other metabolites, which were 
not evaluated in this study. Numerous weaker resonances, in 
particular lipids and macromolecules, were included in the fit. 
The MRSI Voxel Picker (MVP) software suite (Seese et al., 2011) 
was used for MRI/MRSI co-processing. The T1-weighted volume 
and the gray-matter, white-matter, and CSF binary masks were 
imported into MVP as well as the MRSI raw data file and LCModel 
output. For each subject’s MRSI slab, MVP reconstructed the 
T1-weighted volume and displayed it in a guided user interface 
in register with the corresponding MRSI PRESS volume in its 
plane of acquisition. MVP similarly reconstructed each mask 
and computed the volume percent gray matter, white matter, 
and CSF in each MRSI voxel. Then MVP corrected the LCModel-
derived levels of each metabolite for voxel CSF content. Quality 
control of MRSI spectra was also automatically implemented by 
MVP supplemented by operator inspection. Only those spectra 
that exhibited linewidth ≤0.1 ppm and signal-to-noise ratio ≥5 
were retained. Furthermore, within each voxel, only those Glx 
values were retained that were considered reliable by LCModel 
(standard deviation of metabolite signal <20%). Voxels were 
selected by a diagnosis-blind operator on the MVP guided user 
interface in left and right hemispheres for inferior frontal cor-
tex, defined using protocols developed at our center (Blanton 
et al., 2004). Posterior cingulate and precuneal voxels comprised 
a roughly equal mixture of left and right hemispheres. Within 
each structure, MVP averaged the metabolite levels for all vox-
els that contained ≥60 volume percent gray matter and that sat-
isfied the above quality-control criteria.
Statistics
Not all the subjects of Table 1 had usable Glx data for all 4 brain 
regions. In some cases, data were missing, because the scanning 
session was aborted early due to technical difficulties or subject 
compliance. This most affected the medial parietal slab, which 
was run late in the session. Other data were rejected, because 
they failed to meet the above-listed quality-control criteria. 
Consequently, the 2 subject groups were compared for sex, age, 
and smoking not just for the overall sample (Table 1) but also for 
each of the 4 regions individually using only the subjects who 
had usable Glx data for that region. The numbers of subjects 
with usable data for each region are given in Table 2. The χ2 test 
was used to compare sex and independent t test was used to 
compare all other between-group variables. To assess possible 
confounds due to partial-volume effects, volume percent gray 
matter, white matter, and CSF were also compared between 
groups using independent t test in each individual region. Any 
of the aforementioned variables significantly differing between 
the groups was applied as a covariant in subsequent analyses 
in the relevant brain regions. Finally, mean BDI score was com-
pared between groups for the overall sample using independent 
t test (Table 1). Mean BDI score was expected to be much higher 
for the methamphetamine group than for the control group, as 
acute depression is an established clinical feature of metham-
phetamine withdrawal (Newton et al., 2004; Zorick et al., 2010). 
Therefore, BDI score was not used as a covariate in subsequent 
analyses.
 An omnibus approach to multiple comparisons was taken 
for between-group tests of mean Glx. A repeated-measures anal-
ysis of variance was performed with Glx as measure, “region” as 
within-subjects factor (4 levels for the 4 cortical regions), and 
“diagnosis” as between-subjects factor (2 levels: methampheta-
mine and control). This was followed by posthoc t tests com-
paring mean Glx between the 2 groups in each region. For any 
region showing a significant between-group difference in Glx, 
we then ran, within the methamphetamine group, a Spearman 
correlation of Glx vs duration of methamphetamine abuse in 
years partialling age. Finally, we ran a Pearson correlation in the 
Table 2. Subject Numbers, MRSI Voxel Tissue Composition and Glx Levels in Target Cortices.
Posterior Cingulate Precuneus
Methamphetamine Control Methamphetamine Control
subjects 39 17 30 15
gray matter 77.1 ± 2.9 77.5 ± 3.6 73.9 ± 3.3 73.2 ± 2.9
white matter 8.2 ± 4.0 8.2 ± 5.7 7.3 ± 3.5 9.1 ± 3.8
CSF 14.7 ± 4.1 14.2 ± 4.1 18.7 ± 4.0 17.5 ± 4.6
Glx 12.6 ± 1.5* 13.7 ± 1.4 12.2 ± 1.7* 13.2 ± 1.3
Left Inferior Frontal Cortex Right Inferior Frontal 
Cortex
Methamphetamine Control Methamphetamine Control
subjects 41 23 38 20
gray matter 73.5 ± 4.9 72.8 ± 5.4 73.4 ± 4.3 73.8 ± 5.3
white matter 10.7 ± 5.9 12.1 ± 5.4 10.7 ± 5.2 10.7 ± 6.0
CSF 15.8 ± 5.4 15.0 ± 4.9 15.8 ± 5.0 15.3 ± 7.5
Glx 12.4 ± 2.2 12.7 ± 2.3 12.7 ± 2.5* 14.6 ± 2.6
Listed are numbers of subjects with usable Glx data in each target cortex.
Gray matter-, white matter-, CSF-content expressed as percent of total MRSI voxel volume.
Glx levels corrected for voxel CSF-content.
Tissue composition and Glx values are group means ± standard deviation.
Significant between-group comparisons (*P<0.05, post-hoc t-test following R-ANOVA)
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region within the methamphetamine group of Glx vs BDI score. 
The criterion for statistical significance for all tests was P < .05.
Results
Clinical Characteristics
In the overall sample (Table 1), there were no significant between-
group differences in sex or mean age, pack-years of cigarettes, 
or Fagerström score. When retested for subjects having usable 
Glx data in each of the 4 cortical regions, there were again no 
significant between-group differences. Therefore, it was not nec-
essary to use any of these variables as a covariate in subsequent 
analyses. As expected, mean depressive symptoms, as assessed 
by BDI score, were higher for the methamphetamine (13.3 ± 11.5) 
than for the control (1.8 ± 2.5) group (t50.0 = 6.3, P < .0005).
MRSI Voxel Tissue Content
There were no significant between-group differences in volume 
percent gray matter, white matter, or CSF in any region (Table 2). 
When the 2 subject groups were divided into male and female 
subgroups and then compared by diagnosis, there were also no 
significant differences in volume percent gray matter, white 
matter, or CSF in any region. Note that these volume percent-
ages are amounts of gray matter, white matter, and CSF in the 
MRSI sampling volume, which typically occupy only a fraction 
of the target brain region. Thus, these measures are unsuitable 
to quantify atrophy or other volumetric effects on the region 
as a whole. Their purpose, rather, is to ensure that apparent 
between-group differences in metabolite levels are not con-
founded by between-group differences in MRSI voxel tissue 
composition.
Regional Glx Levels and Correlations with Duration 
of Methamphetamine Abuse and BDI
Repeated-measures analysis of variance of Glx levels across the 
4 cortical regions yielded a significant main effect of diagnosis 
(F1,36 = 4.8, P = .035) (Table 2, Figure 2). Posthoc examination of the 
4 target regions revealed significantly lower mean Glx for the 
methamphetamine than the control group in posterior cingulate 
(39 methamphetamine subjects/17 controls with usable data, 
8.1% deficit, t32.5 = 2.7, P = .011), precuneus (30/15, 7.9%, t35.0 = 2.2, 
P = .031), and right inferior frontal cortex (38/20, 12.8%, t37.7 = 2.6, 
P = .013), but not in left inferior frontal cortex (Figure 2). When the 
2 subject groups were divided into male and female subgroups, 
similar regional deficits in Glx were observed for the metham-
phetamine relative to the control group in both sexes in poste-
rior cingulate (male 8.0% deficit, female 7.5%), precuneus (male 
6.6%, female 9.7%), and right inferior frontal cortex (male 15.1%, 
female 9.2%), but not in left inferior frontal cortex (male 3.1% 
surplus, female 7.2% deficit). For males and females together, 
there was a notable (15.4%) right > left asymmetry in inferior 
frontal cortex in Glx within controls (paired t20 = 3.5, P = .014) that 
was not seen in the methamphetamine group (t37 = 0.8, P = .444).
 Within the methamphetamine group, Glx in posterior cin-
gulate decreased with increasing years of abuse (df = 36, r = -0.42, 
P  = .008, partial age) (Figure 2). This relationship was not signifi-
cant in the other 3 regions. In right inferior frontal cortex, Glx in 
Figure 2. (Left) Levels of Glx (glutamate [Glu] + glutamine [Gln]) measured by magnetic resonance spectroscopy imaging (MRSI) in midline (left + right) posterior cingulate 
cortex (upper panel) and right inferior frontal cortex (lower panel) in early (4–7 days) abstinent methamphetamine abusers (circles) and age-and sex-matched healthy 
controls (triangles). Horizontal bars denote group means. Note lower mean Glx in the methamphetamine group in both cortices, 8.1% in midline posterior cingulate 
(t32.5 = 2.7, P = .011), and 12.8% in right inferior frontal cortex (t37.7 = 2.6, P = .013), suggesting local downregulation of brain glutamatergic systems in early abstinence. A simi-
lar Glx deficit (not shown) was observed in precuneus (7.9%, t35.0 = 2.2, P = .031). (Right, upper) Within the methamphetamine sample, Glx in posterior cingulate decreases 
with increasing years of abuse (df = 36, r = -0.42, P = .008, partial age). (Lower) In right inferior frontal cortex, Glx in the methamphetamine sample decreases with increas-
ing depressive symptoms on the Beck Depression Inventory (BDI; df = 38, r = -0.45, P = .005). Metabolite levels in IU corrected for voxel CSF content. *P < .05, **P < .01.
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the methamphetamine group decreased with increasing depres-
sive symptoms on the BDI (df = 38, r = -0.45, P = .005) (Figure  2). 
This relationship was not significant in the other 3 regions.
Discussion
Cortical Glx Deficits
This is 1 of only 2 proton MRSI studies of the brain in subjects 
who had chronically abused methamphetamine; the other is by 
Howells et al. (2014). As noted, several studies used single-voxel 
proton MRS to investigate effects of methamphetamine abuse 
on neurometabolites (Ernst et al., 2000; Nordahl et al., 2002 2005; 
Sekine et  al., 2002; Chang et  al., 2005; Salo et  al., 2007 2011a 
2011b; Sung et al., 2007; Taylor et al., 2007; Sailasuta et al., 2010; 
Cloak et al., 2011; Howells et al., 2014). Most studies predomi-
nantly examined patients who had been long-term abstinent 
from methamphetamine. Similar to Ernst and Chang (2008) and 
Yang et al. (2013), the former finding diminished Glx in anterior 
cingulate of methamphetamine-abusing humans and the latter 
finding it in methamphetamine-exposed monkeys, we focused 
on the acute phase of abstinence. We used short echo-time MRSI 
to assay Glx from multiple cortices at high spatial resolution. 
Poorly accessible inferior frontal cortex was sampled with the 
help of an innovative sagittal-oblique slab prescription. Voxel 
tissue-composition was determined and used to mitigate par-
tial-volume effects, yielding high voxel tissue purity (Table 2).
 This study yielded 3 major findings. The first was modestly 
(7–13%) lower levels of Glx in acute abstinence from metham-
phetamine abuse (vs in the control group) in 3 cerebral corti-
cal regions: posterior cingulate, precuneus, and right inferior 
frontal cortex. Second, in one of these regions, posterior cingu-
late, Glx decreased with increasing years of methamphetamine 
abuse. Third, in another region, right inferior frontal cortex, 
Glx decreased with increasing depressive symptoms. Taken 
together, these findings support the notion advanced by Ernst 
and Chang (2008) of a downregulation of brain glutamatergic 
systems in the early days of withdrawal from methampheta-
mine and suggest that this phenomenon is not limited to the 
anterior middle cingulate.
 The finding of a deficit in Glx in posterior cingulate, precu-
neus, and right inferior frontal cortex of methamphetamine 
abusers (Table  2, Figure  2) extends prior work with imaging 
modalities other than MRSI. In posterior cingulate and pre-
cuneus, 18FDG-PET previously demonstrated elevated glucose 
metabolism in methamphetamine-abusing subjects following 
up to14 days (London et al., 2004) or 14 days to 2 years (Volkow 
et al., 2001; Berman et al., 2008) abstinence from drug. In combi-
nation with these findings, the present results reinforce the view 
that methamphetamine abuse is associated with dysfunction in 
brain areas, such as medial parietal cortex, with sparse dopa-
minergic innervation (Descarries et al., 1987). Glx in the meth-
amphetamine group also was below control levels in the right 
inferior frontal cortex. Notably, this deficit reflected the absence 
of a right > left excess of Glx seen in the controls (Table 2). The 
right inferior frontal gyrus has been linked to response inhibition 
(Aron et al., 2014; but see Swick et al., 2008), a cognitive function 
thought to be impaired in methamphetamine abuse (Monterosso 
et al., 2005; for review, see Baicy and London 2007), and to meth-
amphetamine craving as well as emotion regulation (Tabibnia 
et al., 2011). Although we are unaware of previous MRS studies 
sampling inferior frontal cortex in subjects who had abused 
methamphetamine, in our previous published work, we have 
observed deficits in gray matter in this region in such subjects 
(Thompson et al., 2004; Tabibnia et al., 2011). We did not observe 
Glx effects in left inferior frontal cortex. The present findings add 
to evidence that inferior frontal cortex is particularly affected by 
methamphetamine abuse and/or withdrawal and support our 
previous observations of a lateralization of methamphetamine-
associated pathology (Thompson et al., 2004; Morales et al., 2012), 
perhaps related to the imputed lateralization of function (motor 
language, response inhibition) in this region.
 Our second major finding was that, within the methamphet-
amine group, Glx in posterior cingulate decreased with increas-
ing years of abuse. In anterior middle cingulate, Ernst and 
Chang (2008) found no significant relationship between Glx and 
methamphetamine abuse, operationalized as the logarithm of 
cumulative lifetime exposure. This negative result fortified their 
argument that low Glx levels are a more direct effect of with-
drawal than of abuse per se. Our result does not disagree with 
this interpretation, because if a drop in cortical Glx is induced by 
withdrawal, a greater drop might be seen following more severe 
prewithdrawal abuse. It also may be noteworthy that although 
Ernst and Chang (2008) assessed Glx in the anterior middle cin-
gulate cortex, the finding here was related to an observation in 
posterior cingulate.
 The observation that Glx in the inferior frontal cortex of the 
right hemisphere was negatively associated with BDI score is of 
interest in the context of recent research that has been uncov-
ering links between depression and central glutamatergic sys-
tems, including rapid responses to treatments for otherwise 
refractory depression (Sanacora et al., 2011; Zarate et al., 2013). 
These treatments include most notably NMDA receptor antago-
nists such as ketamine. Within the narrower context of meth-
amphetamine use disorders, severity of depressive symptoms 
positively covaried with relative CMRglc in subgenual and pre-
genual anterior cingulate cortices during early abstinence from 
the drug (London et al., 2004), whereas BDI score covaried with 
relative CMRglc in right inferior frontal cortex within a healthy 
control group. Cortical volume in right inferior frontal gyrus and 
in multiple right-hemisphere, cingulate subregions also was 
below control values in a partially overlapping sample of meth-
amphetamine users (Thompson et al., 2004).
Since the discovery of the “catastrophic reaction” following 
left-hemisphere middle cerebral artery infarcts (Goldstein 1939), 
the inferior frontal cortex has been linked with the lateraliza-
tion of emotion in as yet unclear ways, although the pars orbic-
ularis of this region has been implicated in inhibitory control 
in multiple modalities, including emotion regulation (Tabibnia 
et al., 2011). The right hemisphere is thought to dominate over 
the left in the expression of all or of only negative emotions 
(Hellige, 1993), with right-hemisphere overactivation possibly 
generating negative emotions (Davidson 1992), or depression 
impairing right-hemisphere function (Tucker, 1987). The present 
Glx result adds to evidence associating depression with inferior 
frontal lateralization. Moreover, it points to a linkage between 
depression in acute withdrawal from methamphetamine and 
Glu metabolism, although depressive symptoms may predate 
and possibly predispose an individual to methamphetamine 
use. As conventional serotonergic agents perform poorly in 
treating the depression of methamphetamine withdrawal, the 
poor response to serotonergic treatment correlating with high 
craving for methamphetamine and relapse (Zorick et al., 2011), 
glutamatergic alternatives might be useful for treating this con-
dition. We are unaware of published or ongoing clinical trials or 
case studies involving glutamatergic drugs for methampheta-
mine use disorders, although there is some relevant preclinical 
work (Carroll, 2008; Iijima et al., 2013).
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 Ernst and Chang (2008) reported reduced Glx in anterior 
middle cingulate of methamphetamine users, including meas-
urements during the early abstinence phase examined in the 
present study. Since the anterior middle cingulate was not sam-
pled in the present study, it is not known whether the meth-
amphetamine sample exhibited below-normal Glx in anterior 
middle cingulate along with the other brain regions, although 
it is possible. In any case, the mechanisms proposed by Ernst 
and Chang (2008) to explain reduced Glx in anterior middle cin-
gulate of patients with methamphetamine use disorder also 
likely apply in the cortical regions investigated here. Briefly, the 
mechanisms include loss of glutamatergic neurons, decreased 
Glu synthesis by the Krebs cycle (inhibited mitochondrial func-
tion), reduced astrocyte uptake and recycling of Glu as Gln, and 
increased demand for Glu and Gln as amino acids to repair cell 
structures damaged by methamphetamine. Thus, there may be 
multiple, possibly overlapping, pathophysiological pathways to 
low cortical Glx following methamphetamine abuse. Regarding 
the medial parietal regions, posterior cingulate, and precuneus 
particularly, as discussed by Volkow et  al. (2001), animal stud-
ies indicate that the parietal cortex is especially sensitive to 
methamphetamine toxicity (Pu et al., 1996), including damage to 
pyramidal glutamatergic cells (Commins and Seiden, 1986; Ryan 
et al., 1990). Methamphetamine also upregulates Glu receptors 
in parietal cortex (Eisch et al., 1996), increasing their sensitivity 
to glutamatergic excitotoxicity. These factors may contribute to 
regional drop in Glx. A further factor is methamphetamine tox-
icity mediated by σ-receptors (Kaushal and Matsumoto, 2011), 
which have high density in posterior cingulate (Stone et al., 2006).
 This study has limitations. MRSI was acquired at 1.5 T, making 
segregation of Glx into Glu and Gln more difficult. Although we 
believe that presentation of MRS Glu results is defensible even 
at 1.5 T, we opted for Glx as a metric of regional glutamatergic 
metabolism in this report, since the motivating results of Ernst 
and Chang (2008) and Yang et al. (2013) were expressed as Glx. 
Further work at high field strength is nonetheless encouraged. 
Due to incomplete acquisition and rejection of data not meet-
ing spectral quality or tissue-content standards, Glx values were 
missing for a number of subjects in some brain regions. Actual 
subject numbers analyzed for each region are indicated in Table 2. 
Potential confounds arising from this matter were addressed by 
confirming that the 2 subject groups were still balanced for sex, 
age, smoking, and MRSI voxel tissue-content in each region indi-
vidually after accounting for these missing values. Whereas sin-
gle-voxel MRS typically offers more rapid acquisition with higher 
signal-to-noise ratio, MRSI has the advantage of smaller voxel size 
and hence lower chance of confounding of results due to partial-
volume effects. Our study also has certain uncommon strengths, 
one of these being matching of subject groups for tobacco smok-
ing. Such matching may be critical for any study of glutamater-
gic compounds in methamphetamine abuse. Our work (O’Neill 
et al., 2014) suggests that cigarette smoking, extremely prevalent 
among methamphetamine abusers, is associated with low Glx in 
at least one brain region, the thalamus. Overall, the present inves-
tigation supports the notion of downregulation of glutamatergic 
metabolism in multiple cerebral cortices in very early abstinence 
from methamphetamine; low Glx may be associated with the 
depressive component of the methamphetamine withdrawal 
syndrome, which is presumably an important driver of relapse.
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